Home LiteratureArticle Details
PMID: 10962438 Published · ppublish English Journal Article Research Support, U.S. Gov't, Non-P.H.S.

RAS transformation causes sustained activation of epidermal growth factor receptor and elevation of mitogen-activated protein kinase in human mammary epithelial cells.

International journal of cancer ·Vol. 88 ·No. 1 ·2000-10-01 ·Pages 44-52

Martínez-Lacaci I, Kannan S, De Santis M, Bianco C, Kim N, Wallace-Jones B, Ebert AD, Wechselberger C, Salomon DS

Abstract

Activation of the ras oncogene is an important step in carcinogenesis. Human MCF-10A mammary epithelial cells were transformed with a point-mutated form of the Ha-ras oncogene. Epidermal growth factor receptor (EGFR) phosphorylation levels were chronically elevated after EGF induction and the EGFR ligand-driven internalization rate was slower in Ha-ras transformed MCF-10A cells. Additionally, basal levels of p42/44 mitogen-activated protein kinase (MAPK) expression and enzyme activity were significantly higher in Ha-ras transformed cells, localized predominantly in the nucleus. The anti-EGFR monoclonal antibody (MAb) 225 and the EGFR tyrosine kinase inhibitor PD153035 blocked anchorage-independent growth of Ha-ras transformed cells in soft agar and were more effective when used in combination. The MEK inhibitor PD98059 and anti-erbB-2 MAb L26 also suppressed colony formation of Ha-ras transformed cells in soft agar. Therefore, Ha-ras transformation leads to an augmentation in signaling through the EGFR as a result of an increase in ligand-dependent phosphorylation, a decrease in its internalization and an up-regulation in basal p44/42 MAPK levels. These effects may contribute to uncontrolled growth of Ha-ras-transformed human mammary epithelial cells.

MeSH Terms
Antibodies, Monoclonal/immunology,pharmacology Antibody Specificity Breast/enzymology,metabolism,pathology Cell Line, Transformed Cell Transformation, Neoplastic/genetics,metabolism Cells, Cultured Enzyme Activation Enzyme Inhibitors/pharmacology Epidermal Growth Factor/metabolism,pharmacokinetics ErbB Receptors/genetics,metabolism,physiology Female Gene Expression Regulation Genes, ras/genetics,physiology Growth Inhibitors/pharmacology Humans MAP Kinase Signaling System/physiology Mitogen-Activated Protein Kinase 1/antagonists & inhibitors,biosynthesis,metabolism Mitogen-Activated Protein Kinase 3 Mitogen-Activated Protein Kinases/antagonists & inhibitors,biosynthesis,metabolism Phosphorylation Point Mutation Proto-Oncogene Proteins c-raf/genetics,metabolism Proto-Oncogene Proteins p21(ras)/genetics,metabolism Subcellular Fractions/enzymology Substrate Specificity Transfection
Chemicals
Antibodies, Monoclonal Enzyme Inhibitors Growth Inhibitors Epidermal Growth Factor ErbB Receptors Proto-Oncogene Proteins c-raf Mitogen-Activated Protein Kinase 1 Mitogen-Activated Protein Kinase 3 Mitogen-Activated Protein Kinases HRAS protein, human Proto-Oncogene Proteins p21(ras)
Authors & Affiliations
9 authors, click to expand affiliations / ORCID
Martínez-Lacaci I
Tumor Growth Factor Section, Laboratory of Tumor Immunology and Biology, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA.
Kannan S
De Santis M
Bianco C
Kim N
Wallace-Jones B
Ebert A D
Wechselberger C
Salomon D S
Article Info
Journal
International journal of cancer
Abbr.
Int J Cancer
ISSN
0020-7136
Published
2000-10-01
Pages
44-52
Language
English
Region
United States
NLM ID
0042124
Subset
IM
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com